JP2023102786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023102786A5 JP2023102786A5 JP2023075514A JP2023075514A JP2023102786A5 JP 2023102786 A5 JP2023102786 A5 JP 2023102786A5 JP 2023075514 A JP2023075514 A JP 2023075514A JP 2023075514 A JP2023075514 A JP 2023075514A JP 2023102786 A5 JP2023102786 A5 JP 2023102786A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- ritonavir
- docetaxel
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 5
- 229960000311 ritonavir Drugs 0.000 claims 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229960003668 docetaxel Drugs 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025049063A JP2025094186A (ja) | 2018-12-21 | 2025-03-24 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215488.0 | 2018-12-21 | ||
| EP18215488 | 2018-12-21 | ||
| JP2021536396A JP2022514960A (ja) | 2018-12-21 | 2019-12-18 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536396A Division JP2022514960A (ja) | 2018-12-21 | 2019-12-18 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025049063A Division JP2025094186A (ja) | 2018-12-21 | 2025-03-24 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023102786A JP2023102786A (ja) | 2023-07-25 |
| JP2023102786A5 true JP2023102786A5 (enExample) | 2023-10-31 |
Family
ID=64901398
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536396A Pending JP2022514960A (ja) | 2018-12-21 | 2019-12-18 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
| JP2023075514A Pending JP2023102786A (ja) | 2018-12-21 | 2023-05-01 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
| JP2025049063A Pending JP2025094186A (ja) | 2018-12-21 | 2025-03-24 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536396A Pending JP2022514960A (ja) | 2018-12-21 | 2019-12-18 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025049063A Pending JP2025094186A (ja) | 2018-12-21 | 2025-03-24 | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220071944A1 (enExample) |
| EP (1) | EP3897611A1 (enExample) |
| JP (3) | JP2022514960A (enExample) |
| KR (1) | KR20220004011A (enExample) |
| CN (1) | CN113473982A (enExample) |
| AU (2) | AU2019410062A1 (enExample) |
| BR (1) | BR112021012266A2 (enExample) |
| CA (1) | CA3124319C (enExample) |
| CL (1) | CL2021001635A1 (enExample) |
| IL (1) | IL284225A (enExample) |
| MX (1) | MX2021007480A (enExample) |
| PE (1) | PE20220129A1 (enExample) |
| WO (1) | WO2020127607A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113543781A (zh) * | 2018-12-21 | 2021-10-22 | 莫德拉药物股份有限责任公司 | 通过控制峰值血浆水平使用多西他赛的癌症治疗 |
| GB202201935D0 (en) | 2022-02-14 | 2022-03-30 | Modra Pharmaceuticals B V | Methods and compositions for treating cancer in taxane-resistant patients |
| CN116270617B (zh) * | 2023-03-29 | 2024-01-26 | 济宁医学院附属医院 | Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008291930B2 (en) * | 2007-08-24 | 2014-04-17 | Slotervaart Participaties Bv | Compositions for the treatment of neoplastic diseases |
| GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
| US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| EP2328555A2 (en) | 2008-08-22 | 2011-06-08 | Slotervaart Participaties BV | Compositions for the treatment of neoplastic diseases |
| CN113543781A (zh) * | 2018-12-21 | 2021-10-22 | 莫德拉药物股份有限责任公司 | 通过控制峰值血浆水平使用多西他赛的癌症治疗 |
-
2019
- 2019-12-18 EP EP19828725.2A patent/EP3897611A1/en active Pending
- 2019-12-18 JP JP2021536396A patent/JP2022514960A/ja active Pending
- 2019-12-18 BR BR112021012266-4A patent/BR112021012266A2/pt not_active Application Discontinuation
- 2019-12-18 MX MX2021007480A patent/MX2021007480A/es unknown
- 2019-12-18 CN CN201980090621.4A patent/CN113473982A/zh active Pending
- 2019-12-18 CA CA3124319A patent/CA3124319C/en active Active
- 2019-12-18 US US17/416,946 patent/US20220071944A1/en active Pending
- 2019-12-18 WO PCT/EP2019/086125 patent/WO2020127607A1/en not_active Ceased
- 2019-12-18 PE PE2021001053A patent/PE20220129A1/es unknown
- 2019-12-18 KR KR1020217022969A patent/KR20220004011A/ko not_active Ceased
- 2019-12-18 AU AU2019410062A patent/AU2019410062A1/en not_active Abandoned
-
2021
- 2021-06-18 CL CL2021001635A patent/CL2021001635A1/es unknown
- 2021-06-20 IL IL284225A patent/IL284225A/en unknown
-
2023
- 2023-05-01 JP JP2023075514A patent/JP2023102786A/ja active Pending
- 2023-07-14 AU AU2023204693A patent/AU2023204693A1/en not_active Abandoned
-
2025
- 2025-03-24 JP JP2025049063A patent/JP2025094186A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023102786A5 (enExample) | ||
| Bayet-Robert et al. | Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer | |
| JP2025020147A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| ES2576289T3 (es) | Nanopartículas de paclitaxel y albúmina en combinación con bevacizumab contra el cáncer | |
| JP2022180461A5 (enExample) | ||
| JP2023102787A5 (enExample) | ||
| JP2003533485A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| CN109985237A (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| JP2023102786A (ja) | ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療 | |
| JP2023102787A (ja) | 癌の治療におけるドセタキセルの長期使用 | |
| CN105963637A (zh) | 隐丹参酮联合姜黄素在制备肿瘤治疗药物中的应用 | |
| JP2015507020A5 (enExample) | ||
| US10080807B2 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin C | |
| JP2024016209A5 (enExample) | ||
| JP2010504307A5 (enExample) | ||
| CN105796638B (zh) | 冬凌草甲素联合隐丹参酮在制备白血病治疗药物中的应用 | |
| KR102157771B1 (ko) | 다이설피람을 포함하는 항암용 조성물 | |
| JP2022542725A (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| CN117919262A (zh) | 2′-岩藻糖基乳糖作为一种抗肿瘤辅助药物与抗pd-1药物联合用于制备治疗结肠癌药物的用途 | |
| WO2014047780A1 (zh) | 含有芹菜素及芹菜素类衍生物和冬凌草甲素及冬凌草甲素类衍生物的药物组合物及其应用 | |
| Khuri et al. | Novel agents and incremental advances in the treatment of head and neck cancer | |
| CN111728960B (zh) | 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用 | |
| CN119033797B (zh) | 抗肿瘤组合物及其应用 |